Buy Intersect ENT (XENT) Ahead Of SINUVA Reminbursement Decision In Nov - Piper Jaffray
Tweet Send to a Friend
Piper Jaffray analyst, Matt O\'Brien, reiterated his Overweight rating on shares of Intersect ENT (NASDAQ: XENT) after a slower-than-expected Sinuva ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
